journal article·2021-11-24Open access

Altered Glycan Expression on Breast Cancer Cells Facilitates Infection by T3 Seroptype Oncolytic Reovirus

Danahe Mohammed, Melanie Koehler, Andra C. Dumitru, Pavithra Aravamudhan, Danica M. Sutherland, Terence S. Dermody, David Alsteens

Nano Letters· Volume 21· Issue 22

Abstract

Breast cancer is the most common cancer in women. Although current therapies have increased survival rates for some breast cancer types, other aggressive invasive breast cancers remain difficult to treat. As the onset of breast cancer is often associated with the appearance of extracellular markers, these could be used to better target therapeutic agents. Here, we demonstrated by nanobiophysical approaches that overexpression of α-sialylated glycans in breast cancer provides an opportunity to combat cancer cells with oncolytic reoviruses. Notably, a correlation between cellular glycan expression and the mechanical properties of reovirus attachment and infection is observed in a serotype-dependent manner. Furthermore, we enhance the infectivity of reoviruses in malignant cells by the coinjection of α-sialylated glycans. In conclusion, this study supports both the use of reoviruses as an oncolytic agent in nanomedicine and the role of α-sialylated glycans as adjuvants in oncolysis, offering new perspective in oncolytic cancer therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Virus-based gene therapy research · Viral gastroenteritis research and epidemiology · Cancer Research and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Louvain Institute of Biomolecular Science and Technology (LIBST), Université Catholique de Louvain, 1348 Louvain-la-Neuve, Belgium

Department of Pediatrics, University of Pittsburgh School of Medicine, 4401 Penn Avenue, Pittsburgh, 15224 Pennsylvania United States

Institute of Infection, Inflammation, and Immunity, UPMC Children’s Hospital of Pittsburgh, 4401 Penn Avenue, Pittsburgh, 15224 Pennsylvania United States

Department of Pediatrics and Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, 4401 Penn Avenue, Pittsburgh, 15224 Pennsylvania United States

Walloon Excellence in Life sciences and Biotechnology (WELBIO), 1300 Wavre, Belgium

Funding

Children's Hospital of Pittsburgh · U.S. Public Health Service · Heinz Endowments · Universit?? Catholique de Louvain · Fonds De La Recherche Scientifique - FNRS · H2020 European Research Council · Research Department of the Communaut?? fran??aise de Belgique

References (36)

Show source-provided references
1. 10.1007/s10719-016-9755-210.1007/s10719-016-9755-2 ↗
2. 10.1016/j.trecan.2020.04.00210.1016/j.trecan.2020.04.002 ↗
3. 10.1016/j.bbcan.2020.18846410.1016/j.bbcan.2020.188464 ↗
4. 10.1002/jlb.40.1.9710.1002/jlb.40.1.97 ↗
5. 10.1073/pnas.96.12.695310.1073/pnas.96.12.6953 ↗
6. 10.1016/S0966-842X(03)00178-110.1016/S0966-842X(03)00178-1 ↗
7. 10.1128/JVI.77.24.13361-13375.200310.1128/JVI.77.24.13361-13375.2003 ↗
8. 10.1016/j.virol.2015.06.01810.1016/j.virol.2015.06.018 ↗
9. 10.1038/s41467-019-12411-210.1038/s41467-019-12411-2 ↗
10. 10.1128/jvi.28.2.444-449.197810.1128/jvi.28.2.444-449.1978 ↗
11. 10.1038/onc.2015.13610.1038/onc.2015.136 ↗
12. Bos J. L. · Cancer Res. · 1989 · 49 · 4682
13. 10.1128/JVI.01613-2010.1128/JVI.01613-20 ↗
14. 10.3332/ecancer.2020.114910.3332/ecancer.2020.1149 ↗
15. 10.1016/j.omto.2020.08.00810.1016/j.omto.2020.08.008 ↗
16. 10.3390/cancers1211321910.3390/cancers12113219 ↗
17. 10.21873/anticanres.1475310.21873/anticanres.14753 ↗
18. 10.1021/acs.nanolett.0c0460910.1021/acs.nanolett.0c04609 ↗
19. 10.1016/S0092-8674(01)00231-810.1016/S0092-8674(01)00231-8 ↗
20. 10.1371/journal.ppat.100307810.1371/journal.ppat.1003078 ↗
21. 10.1126/science.113759210.1126/science.1137592 ↗
22. Evans E. · 2002 · 14510.1007/3-540-45701-1_4 ↗
23. 10.1002/advs.20200264310.1002/advs.202002643 ↗
24. 10.1038/s41598-021-95740-x10.1038/s41598-021-95740-x ↗
25. 10.1073/pnas.191351111610.1073/pnas.1913511116 ↗
26. 10.1038/nnano.2007.38810.1038/nnano.2007.388 ↗
27. 10.1242/bio.01340910.1242/bio.013409 ↗
28. 10.1038/nrc398210.1038/nrc3982 ↗
29. 10.1016/j.aca.2018.04.07210.1016/j.aca.2018.04.072 ↗
30. 10.1038/nrmicro334610.1038/nrmicro3346 ↗
31. 10.1038/bjc.1995.19910.1038/bjc.1995.199 ↗
32. 10.1128/JVI.00895-0610.1128/JVI.00895-06 ↗
33. 10.3892/or.2011.119210.3892/or.2011.1192 ↗
34. 10.3322/caac.2166010.3322/caac.21660 ↗
35. 10.1016/j.pbiomolbio.2019.11.00710.1016/j.pbiomolbio.2019.11.007 ↗
36. 10.3390/ijerph1706207810.3390/ijerph17062078 ↗